Dr. Daniel Q. Huang graduated from the Yong Loo Lin School of Medicine, National University of Singapore. He served as the Chief Resident in NUH Internal Medicine and was selected for the Singapore Chief Residency Programme. He completed a fellowship in Gastroenterology at NUH. Currently, he leads hepatocellular carcinoma research in the Division of Gastroenterology and is experienced in diagnostic and therapeutic endoscopy.
Dr. Huang’s research interest is in the early detection and prevention of hepatocellular carcinoma in metabolic dysfunction-associated steatohepatitis (MASH) and viral hepatitis. Dr. Huang is working on non-invasive strategies to risk-stratify MASH and hepatocellular carcinoma by leveraging advanced imaging, genomic, and RNA-based approaches. Dr. Huang has published several key studies on the indeterminate phase, or grey zone, of hepatitis B, contributing to an expansion of the treatment indications for chronic hepatitis B in the 2024 World Health Organization guidelines to include the indeterminate phase. Dr. Huang developed the MASH Resolution Index, a non-invasive index to determine MASH resolution, which is now utilised as an endpoint in clinical trials for MASH. Dr. Huang has co-authored clinical practice guidelines for the American Gastroenterology Association (AGA) and is contributing to several guidance statements of the Asia Pacific Association for the Study of the Liver (APASL).
Dr. Huang has published more than 200 peer-reviewed articles, including several as corresponding author in leading journals such as Hepatology, the Journal of Hepatology, Nature Reviews Gastroenterology and Hepatology, Gut, and the Lancet Oncology. He has received awards for his research from the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL). Dr. Huang is a frequently invited speaker at regional and international scientific meetings. His research is funded by several grants from the National Medical Research Council, and he is the PI of multiple translational and clinical studies in MASH and HCC. Dr. Huang leads a research network in Asia studying hepatocellular carcinoma. He serves as the Hepatology chair of the Emerging Leaders Committee (Asia Pacific Gastroenterology Association) and as an Associate Editor of Alimentary Pharmacology and Therapeutics.
Area of Interest:
1. Huang D.Q., Tran A, Yeh ML, et al. Antiviral therapy substantially reduces hepatocellular carcinoma risk in chronic Hepatitis B patients in the indeterminate phase. Hepatology. 2023 May 16. doi: 10.1097/HEP.0000000000000459.
2. Tan EY et al., and Huang DQ. Liver cancer in 2021: Global burden of disease study. J Hepatol. 2024 Oct 30:S0168-8278(24)02652-7.
3. Huang, D. Q., Wilson, A.W, Behling, C. et al. Fibrosis Progression Rate in Biopsy-proven Nonalcoholic Fatty Liver Disease among People with Diabetes versus People without Diabetes: A Multicenter Study. Gastroenterology (2023).
4. Loomba R, …. and Huang DQ. MASH Resolution Index: development and validation of a non-invasive score to detect histological resolution of MASH. Gut. 2024 Jul 11;73(8):1343-1349. doi: 10.1136/gutjnl-2023-331401.
5. Huang, D. Q., Fowler, K. J., Liau, J., et al. (2022). Comparative efficacy of an optimal exam between ultrasound versus abbreviated MRI for HCC screening in NAFLD cirrhosis: A prospective study. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 55(7), 820-827. doi:10.1111/apt.16844
6. Huang DQ, Wong VWS, Rinella ME, et al. Metabolic dysfunction-associated steatotic liver disease in adults. Nat Rev Dis Primers. 2025 Mar 6;11(1):14.
7. Huang D.Q., Nourredin N, Ajmera V, et al. Type 2 Diabetes Mellitus, Hepatic Decompensation and Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease: Individual Participant Data Meta-analysis. The Lancet Gastroenterology and Hepatology 2023.
8. Huang DQ, Li X, Le MH et al. Natural History and Hepatocellular Carcinoma Risk in Untreated Chronic Hepatitis B Patients With Indeterminate Phase. Clin Gastroenterol Hepatol. 2022 Aug;20(8):1803-1812.e5
9. Zheng M, Huang D.Q., Konkwo C, et al. Genomic analysis of lean individuals with NAFLD identifies monogenic disorders in a prospective cohort study. JHEP Rep. 2023 Feb 2;5(4):100692.
10. Huang, D. Q., Muthiah, M. D., Zhou, L et al. (2021). Predicting HCC Response to Multikinase Inhibitors With In Vivo Cirrhotic Mouse Model for Personalized Therapy. Cellular and Molecular Gastroenterology and Hepatology, 11(5), 1313-1325. doi:10.1016/j.jcmgh.2020.12.009
